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ABSTRACT: The lung is a portal of entry for numerous microbial pathogens, against
which evolution has created an adequate innate and adaptive immune response.
Dendritic cells (DCs) are central to the integration of innate and specific immunity.
These cells are located within the epithelium and interstitium of the lung where they are
influenced by the innate immune system.
Upon recognition and internalization of microbial antigens, DCs migrate to the
draining lymph nodes of the lung to initiate the specific cellular and humoral immune
response. By their capacity to integrate stimuli derived from the pathogen, the host and
the environment, they are specialized to induce a protective immune response while at
the same time avoiding damage to the host.
It is becoming increasingly clear that dendritic cells are involved in the induction of
immunity to viruses, bacteria, mycobacteria and fungi. Some pathogens subvert the
function of dendritic cells to escape immune recognition. Not surprisingly, if dendritic
cell function fails, the consequence for the host is immunodeficiency.
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The lung is continuously exposed to the outside
world and is a portal of entry for viral, bacterial, and
fungal infection. Throughout evolution, an extensive
defence mechanism has been developed to protect
humans from these potentially lethal assaults. In its
most primitive form, present also in invertebrates,
the defence system consists mainly of nonspecific
mechanisms, such as antibacterial peptides (a- and
b-defensins), mannose binding protein, lysozyme,
lactoperoxidase, opsonizing collectins (e.g. surfactant),
activation of complement, and interferons. Later, the
innate nonspecific cellular defence system evolved. This
important aspect of pulmonary immunity consists of
phagocytic cells (alveolar macrophages (AMs), neu-
trophils, eosinophils) and natural killer (NK) cells.
They have the capacity to recognize and neutralize
bacterial antigen or virus-infected cells. These cells
are endowed with so-called pattern recognition
receptors, which are encoded in the germline deoxy-
ribonucleic acid (DNA) of the species and have been
selected through evolution to recognize conserved
bacterial products (cell wall constituents, bacterial
DNA motifs) or viral motifs (double-stranded ribo-
nucleic acid (RNA)) [1]. Finally, the adaptive spe-
cific cellular immune response, which first appeared
in higher vertebrates, provided humans with T-
and B-lymphocytes and the exceptional capacity to
recognize a plethora of foreign- and self-antigen by
the process of clonal rearrangement and somatic
mutation of their respective T-cell receptor (TCR)
and immunoglobulin genes. The function of adaptive
immunity is to strengthen and regulate the innate
defence mechanisms and to build immunological
memory so that subsequent challenges are efficiently
overcome.
The evolution of the immune system and the
environmental pressures upon it have created an
extraordinarily complex regulatory system, in which
molecules and cells of the nonspecific line of defence
reciprocally influence the lymphocytes of the adaptive
immune response to induce an optimally protective
immune response, while at the same time avoiding
tissue-damaging autoimmunity [2]. Dendritic cells
(DCs) are a particular group of cells of the innate
defence system that are central to the integration of
nonspecific and specific immunity [2, 3]. These pro-
fessional antigen-presenting cells (APC) are located at
sites of the body where maximal microbial encounter
occurs, such as the skin, gut and lung. In contrast to
T- and B-lymphocytes, DCs have retained many of the
pattern recognition receptors of the ancient immune
system and have the unique capacity to sense stimuli,
such as tissue damage, necrosis, bacterial and viral
infection. This review describes the role of lung DCs
in the initiation and control of pulmonary immunity
to infection.
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T-lymphocyte activation and the need for antigen-
presenting dendritic cells
Naive T-lymphocytes of the adaptive immune res-
ponse need DCs to become fully activated. Circulating
naive T-lymphocytes have a limited capacity to leave
the blood stream and migrate into peripheral tissues.
Instead, they extravasate through specialized high
endothelial venules in the T-cell area of the central
lymphoid structures before re-entering the blood-
stream via the efferent lymphatics. By this migratory
behaviour, they are spatially separated from the
antigen at the portal of entry of infection (e.g. skin
or mucous membranes for most naturally occurring
infections) [4]. Therefore, an important requirement
that precedes the induction of adaptive immunity is
the transport of antigen from the site of initial
exposure to the T-cell area of the draining lymph
nodes. Although some microbes can directly gain
access to these nodes, the transportation of antigen via
the afferent lymphatics is a specialized function of
DCs [5, 6].
The TCR on T-lymphocytes can only recognize
antigen in the context of major histocompatibility
complex (MHC) molecules. A primary function of
the APC is to recognize, internalize and efficiently
process the antigen into immunogenic peptides for
presentation on MHC class I and class II molecules
(fig. 1) [7]. Immature DCs express various receptors,
such as calcium-type lectin receptors (mannose rece-
ptor, DEC-205, langerin, dectin), immunoglobulin
receptors and complement receptors, which can be
used for receptor-mediated endocytosis, macropino-
cytosis or phagocytosis of exogenous antigens [8].
Entry via these receptors targets antigen to a
specialized MHC class II containing endocytic com-
partment (MIIC) where exogenous antigen is loaded
onto MHC class II molecules and subsequently
targeted to the cell surface, especially when the
antigen is delivered in an inflammatory context [8].
The capacity to take up antigen is a feature of
immature DCs residing in peripheral tissues, and is
largely lost during the migration of DCs into the
draining lymph nodes. This way, immature DCs
effectively make a "snapshot" of the antigens present
in a peripheral inflammatory site. Following migra-
tion into the draining lymph nodes, the mature DC
becomes a reporter of its earlier environment and
displays the immunogenic peptides picked up in the
periphery in the cleft of MHC class I and MHC class
II molecules to the TCR on the responding T-cell [4].
Because of this function, DCs have been aptly called
"the sentinels of the immune system". Compared with
B-cells and macrophages, DCs are extremely efficient
in rapidly generating surface peptide-MHC ligands
after exposure to exogenous antigen [9].
In addition to TCR ligation by peptide-MHC
(signal 1), T-lymphocytes need a so-called costimula-
tory signal 2, which is provided by the concerted
action of costimulatory molecules expressed on the
surface of the mature DC interacting with reciprocal
receptors on the naive T-cell (fig. 1) [3, 10]. These
interactions take place in the draining lymph nodes
and are important for clonal expansion, differentia-
tion, and avoidance of anergy in T-cells [7]. Upon
initial encounter of a DC with a T-cell, adhesion
molecules, such as DC-specific ICAM-3 grabbing
nonintegrin (DC-SIGN) and CD54 (intercellular
adhesion molecule (ICAM)-1), interact with leukocyte
functional associated antigen (LFA)-3 and CD11a/
CD18 (LFA-1) to retain the naive T-cell and to
approximate the two cell types. This nonspecific
interaction is of sufficient strength to allow the initial
screening of the low-affinity TCR for recognition of
its specific peptide-MHC on the DC [11]. In very close
proximity to the peptide-MHC, DCs express CD80
and CD86, which gives an activating signal to CD28
on the naive T-cell [7]. Upon TCR recognition and
CD28 stimulation, T-cells produce interleukin (IL)-2
to proliferate and upregulate the expression of CD40L.
The latter molecule is a member of the tumour
necrosis factor (TNF) receptor family, and signals to
CD40 on DCs to increase the production of cytokines
(e.g. IL-12) and the expression of CD80 and CD86,
further intensifying the interaction [12]. Further down-
stream of the cascade, membrane interactions involve
other members of the TNF-receptor family (OX40L/
OX40, tumour necrosis factor related activation-
induced cytokine (TRANCE)-R/TRANCE, 4-1BBL/
4-1BB), which induce mutual activation, differentia-
tion and survival of DCs and T-cells [13, 14]. Soluble
products, such as IL-1b, IL-6, TNF-a and substance
P, are released in what has been aptly called the
immunological synapse forming between the APC
and the naive T-cells, efficiently contributing to
costimulation [15].
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Fig. 1. – The interaction of dendritic cells (DCs) with naive T-cells.
DCs capture foreign antigen using a variety of pattern recognition
receptors and process the antigen for delivery onto major
histocompatibility complex (MHC) antigens. Foreign antigens are
loaded onto MHC class II in an MHC class II rich compartment
(MIIC). T-lymphocytes need two signals to become activated. The
first signal is the recognition of the antigen-MHC by the T-cell
receptor (TCR). The second signal is a costimulatory signal
provided by interaction of ligands on the DC to counter-receptors
on the T-cell. Recognition of signals 1 and 2 occurs in the drain-
ing lymph nodes and leads to T-cell proliferation, differentiation
and migration to the peripheral tissues. DC-SIGN: DC-specific
ICAM-3 grabbing nonintegrin; ICAM: intercellular cell adhesion
molecule; TRANCE: tumour necrosis factor related activation-
induced cytokine; IgG: immunoglobulin-G.
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Dendritic cells determine the outcome of T-cell priming
T-lymphocyte responses are operationally divided
on the basis of the cytokines produced and the
functional effects exerted after encounter of antigen-
specific T-cells with antigen [16]. CD4z T-helper
(Th)1 lymphocytes are effector cells that predomi-
nantly secrete IL-2, interferon (IFN)-c and TNF-b
to activate macrophages and cytotoxic T-cells. CD4z
Th2 lymphocytes secrete IL-4, IL-5, IL-6, IL-9,
IL-10 and IL-13 to induce a predominantly humoral
immune response, sometimes dominated by the
formation of immunoglobulin (Ig)-E. Additionally, it
is thought that Th2 cells are important for mounting
an eosinophilic response and for the expulsion of
gastrointestinal parasites [17]. As DCs carry antigen
from the periphery to the draining lymph node for
presentation, it is not surprising that they are crucial
in instructing naive precursor Th0 cells to become
either Th1 or Th2 cells [18, 19] (fig. 2). The most
critical factors for determining Th differentiation
during infection are the cytokine milieu at the site
of infection, the type and dose of infecting organ-
ism, the natural route of exposure, and the genetic
background, age and prior infection history of the
host. IL-12, IFN-c and IL-18 are critical for the
development of polarized Th1 responses, as illustrated
by reduced Th1 responses in mice in which these genes
were deleted [17, 20]. Conversely, IL-4 acting in
concert with IL-6 is crucial for Th2 development
[21]. However, DCs have not been shown to produce
IL-4, so the early sources of this cytokine are probably
the naive T-cell, or cells of the innate immune system,
such as NK1.1 T-cells or mast cells [17]. The develop-
ment of Th2 responses by naive T-cells could be the
default pathway in the absence of IL-12 production by
DCs [22].
In addition to the production of polarizing cyto-
kines by DCs, it has been suggested that costimulatory
molecules expressed on the surface of the DC are also
essential for determining Th differentiation, although
considerable controversy surrounds this issue. In this
context, ICAM-1 and CD40 favour Th1 development,
whereas OX40L, T1/ST2L, and perhaps CD86
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Fig. 2. – Differentiation of T-helper (Th) responses by dendritic cells (DCs). B7RP: B7-related protein; CTL: cytotoxic lymphocyte;
dsRNA: double-stranded ribonucleic acid; LPS: lipopolysaccharide; NK: natural killer cell; PGE2: prostaglandin E2; IFN: interferon; IL:
interleukin; TNF: tumour necrosis factor; Ig: immunoglobulin; ICAM: intercellular cell adhesion molecule; CpG: Cytosine-p-Guanine;
eosino.: eosinophil.
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promote Th2 development [19, 22]. To complicate
things further, there seem to be different develop-
mental lineages of DCs, each inducing different Th
responses, hence the termination DC1 and DC2. In
the mouse, spleen-derived DC1s are of lymphoid
origin, express CD8azand produce large amounts of
IL-12, leading to Th1 responses. Conversely, DC2s
are myeloid-derived, express CD11b and produce very
little IL-12 [23]. This is the complete opposite in
humans. DC1s are monocyte-derived cells and, there-
fore, of myeloid origin, whereas DC2s express T-cell
markers and are probably of lymphoid origin [24].
The lineage difference of DCs cannot, however, be the
only explanation for the Th1/Th2 decision. It has
indeed been shown that rodent myeloid DCs (i.e.
DC2s) produce IL-12 upon proper stimulation and
become strong stimulators of Th1 cells [25, 26].
Dendritic cells indirectly and directly stimulate B-cell
responses
Although naive B-cells can recognize antigen
through their B-cell receptor, they often need cognate
CD4z Th cell help before they can become fully
activated and perform Ig isotype switching. In the
mouse, Ig switching towards production of opsonizing
antibodies IgG2a requires Th1 CD4z cells, whereas
switching towards neutralizing IgG1 or anaphylactic
IgE requires Th2 CD4z cells. Therefore, DCs have
critical roles: they induce migration and activation of
different subsets of CD4z T-cells, activate B-cell
activation and promote Ig switching [26, 27]. More-
over, recent studies have shown that DCs can carry
unprocessed antigen from the periphery to the B-cell
area of lymph nodes for direct presentation to
recirculating naive B-cells and for inducing the
survival of plasmablasts [28]. Germinal centres con-
tain a particular subset of germinal centre DCs that
can influence germinal centre T-cells during memory
B-cell generation [29].
The airway dendritic cell network under baseline
conditions
Studies in rodents and humans have shown that
an extensive network of bonemarrow-derived DCs
reside within the mucosa of the nose and the large
conducting airways (fig. 3), the alveolar lumen and
septum, and the connective tissues surrounding blood
vessels and pleura [30–33]. Considerable phenotypic
and functional heterogeneity exist in DCs within these
compartments. Mucosal DCs are equipped with
phagocytic receptors and have a rapid turnover rate,
reflecting the continuous sampling for antigen and
prompt migration of these cells to the draining lymph
nodes [5, 34]. Some intraepithelial DCs in humans
show characteristic Birbeck granules and have been
called Langerhans9 cells, by analogy with the skin
DCs. In contrast, alveolar wall DCs have a slower
turnover time and have not (yet) been shown to
migrate into the draining lymph nodes of the lung.
As for all DCs that reside in the periphery, lung
DCs have an immature phenotype, specialized for
antigen uptake and recognition, but not yet capable of
stimulating naive T-cells, because they lack costimu-
latory molecules [26, 30, 31, 35]. Although the precise
regulatory mechanisms that keep DCs in an immature
state are largely unknown, it is proposed that: 1) as
airway DCs reside in the lateral intercellular space
formed by the basal layer of epithelial cells, it is very
likely that mediators (prostaglandin (PG)E2, IL-10 or
nitric oxide (NO)) or membrane ligands (epithelial
cadherin) expressed by epithelial cells are critical for
downregulating airway DC function [26, 36]; and 2)
an equally critical, but largely unexplored mechanism
could be the network of unmyelinated nerve endings
that also resides within the lateral intercellular spaces
and interacts with airway DCs [37]. This network
contains vital neuromediators such as calcitonin-gene
related peptide (CGRP) and substance P, which are
important for the crosstalk between nervous and
immune systems [15]. Indeed, it has been shown that
the baseline function of Langerhans9 cells in the skin is
suppressed by CGRP-containing nerve endings [38].
Separate studies by HOLT and coworkers [31, 39]
have focused on the AM as playing a critical role in
regulating the function of alveolar wall DCs, by
secreting a number of suppressive molecules, such as
NO, transforming growth factor (TGF)-b, 1a,25-
dihydroxyvitamin D3, PGE2 and IL-1 receptor
antagonist [31, 39]. Moreover, AMs also directly
inhibit the proliferation of T-cells, while allowing
partial activation [40]. The strongest arguments for a
suppressive role come from studies in rodents where
AMs were depleted in vivo by inhalation of toxic
liposomes. In these animals, the response to innoc-
uous protein antigens was greatly enhanced and
accompanied by tissue damage to the alveolus [39,
41]. It is thought that the suppressive properties of
AMs serve to protect the delicate gas exchange
mechanism of the alveolus from being damaged by
overtly vigorous inflammatory reactions to inhaled
nonpathogenic antigen.
In the absence of infection or inflammation, there
seems to be a continuous migration of DCs from the
Fig. 3. – The dendritic cell (DC) network in the conducting air-
ways. Mouse tracheal whole mounts were stained with moAb M5/
114 for major histocompatibility complex class II molecules (I–E)
(original magnification 6400). Numerous DCs with long delicate
processes can be seen throughout the conducting airways.
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airways into the draining lymph nodes [6, 34]. One
explanation could be that DCs continuously sample
the environment for incoming antigens, even under
baseline conditions. The localization of immature
airway DCs, extending cell projections to the upper
layers of the airway epithelium (fig. 3), and the
capture of harmless inhaled proteins is consistent
with this function [31]. Alternatively, by analogy with
the gut and internal organs, an explanation for the
continuous migration could be that immature DCs
capture bronchial epithelial cells that have become
apoptotic as part of their normal turnover. The
transportation of apoptotic bodies and the subsequent
presentation by DCs in the absence of infection might
induce peripheral tolerance to self-antigens derived
from bronchial epithelial cells. This would protect the
immune system from mounting an immune response
to self-antigen when bronchial epithelial cells are
rendered apoptotic or even necrotic by infection with
respiratory viruses or bacteria [2, 42]. Whether the
induction of tolerance would be a function of the
migrating DC or occurs only after transfer of self-
antigen from migrating lung DCs to resident lym-
phoid DCs remains to be solved. These nonmigratory
lymphoid DCs have been implicated in the regulation
of central (i.e. thymic) and peripheral tolerance to
self-antigen within the CD4 and CD8 pool [2].
The lung dendritic cell network under inflammatory
conditions: induction of immunity
Under inflammatory conditions, the function of the
lung DC network changes dramatically (fig. 4). In
rodents, it has been shown that exposure to the
mycobacterium bacillus Calmette-Gue´rin (BCG) [43],
Moraxella catarrhalis [44], Bordetella pertussis [45],
heat-killed Listeria monocytogenes, bacterial lipopoly-
saccharide (LPS) [30], Mycoplasma spp. (unpublished
data), Sendai virus [46], influenza virus [47], and
allergen [48] occassionally induces marked increases in
the numbers and activation status of airway DCs. The
mechanisms by which immature DCs are recruited
into the lung are largely unknown. Based upon in vitro
and animal studies, it is very likely that monocytic
precursors are recruited from the bloodstream and
acquire an immature DC phenotype after transen-
dothelial migration into the tissues and exposure to
DC-differentiating factors [49].
The signals that attract these immature DCs are
largely produced by the epithelium and stromal cells
(myofibroblasts) of the airways and potential path-
ways could include the following. 1) Lung inflamma-
tion and tissue damage induced by microbial invasion
or lipopolysaccharide (LPS) can be accompanied by
expression of inflammatory chemokines, such as
macrophage inflammatory protein (MIP)-1a and -b,
monocyte chemotactic protein 1–4, and regulated
upon activation, normal T-cell expressed and secreted
(RANTES), which have all been shown to be
chemotactic for immature DCs [45, 50, 51]. However,
the chemokine MIP-3a, which is expressed in airway
mucosal cells, is probably the most critical factor in
attracting immature lung DCs via a chemokine
receptor (CCR)6-dependent mechanism [51]. 2) Med-
iators of the innate immune system can similarly and
logically attract DCs into the mucosa. The family of
antimicrobial epithelial b-defensins is expressed in
the bronchial epithelial cells of nearly all vertebrates,
where they can be released in high concentrations
upon microbial invasion or upregulated by stimu-
lation with LPS and TNF-a. Recently, it was
shown that human b-defensin-2 (HBD2) has strong
chemotactic activity on immature DCs via a CCR6-
dependent mechanism, linking direct antibacterial
effects with induction of adaptive immunity [52].
Alternatively, bacterial activation of the alternative
complement pathway generates C5a, which is chemo-
tactic for immature DCs and a number of inflamma-
tory cells [45, 50]. 3) Finally, microbial invasion also
induces the release of cytokines and DC growth
factors from resident cell types. TNF-a acts as an
important mediator of DC influx, possibly by indu-
cing chemokines, HBD2, platelet activating factor and
by increasing the expression of cell adhesion molecules
on endothelial cells. An important role for epithelial
granulocyte macrophage colony stimulating factor
(GM-CSF) is suggested by the finding that adenoviral
delivery of this cytokine to the airways induces
dramatic changes in the number and immunostimu-
latory capacity of airway and interstitial DCs ([53]
and the authors9 unpublished data) and the fact that
GM-CSF accelerates the differentiation of monocytes
into immunostimulatory DCs in the lung vascular
bed [49].
The induction of inflammation by microbes in the
lung accompanies the induction of immunity because:
1) immature DCs that have recognized antigen are
induced to migrate via the afferent lymphatics into the
draining lymph nodes of the lung; and 2) DCs are
activated to express the necessary costimulatory
molecules (CD80, CD86, see earlier) for stimulating
naive T-cells. The molecular mechanisms regulating
this maturation process are slowly being elucidated.
The pattern recognition receptors expressed on imma-
ture DCs can sense microbial danger and tissue
damage and signal via the conserved Toll-like receptor
(TLR) signal transduction pathway, effectively lead-
ing to activation of the nuclear factor (NF)-kB
transcription factors, and cellular maturation [1, 54].
The Toll protein was originally described in the fruit
fly Drosophila melanogaster, where it leads to activa-
tion of NF-kB-like kinases, leading to the production
of antifungal peptides. Similar proteins that confer
disease resistance have been found in plants. Thus,
Toll proteins represent a host defence mechanism that
has been conserved over hundreds of millions of years
of evolution. One such pattern-recognition receptor
expressed by DCs is the LPS receptor, which consists
of (soluble) CD14 that binds Gram-negative LPS
complexed to LPS binding protein and signals via the
transmembrane TLR-4 receptor. A similar mechanism
applies to bacterial peptidoglycan from Gram-positive
cell walls, which binds to CD14 and signals via the
TLR-2 [55]. Other factors, such as unmethylated
Cytosine-p-Guanine (CpG) motifs in bacterial DNA
or double-stranded viral RNA, are strong stimulators
of innate immunity and maturation factors for DCs
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[56, 57]. Maturation can also be induced by tissue
damage and its accompanying release of oxygen
radicals, heat shock proteins (HSP) and changes in
the balance between suppressive (IL-10, PGE2, NO)
and inflammatory mediators (TNF-a, IFN-a, GM-CSF,
IL-1) [3, 22, 36, 54]. In this respect, it is interesting to
note that HSP60, endogenously released by tissue
damage, also signals via CD14 and TLR-4 [54].
It is critical that DCs that have recognized and
taken up foreign antigen migrate to the draining
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Fig. 4. – Induction of the antimicrobial immune response. 1. Upon exposure to microbial stimuli, epithelia produce macrophage
inflammatory protein (MIP)3a and b-defensin to attract chemokine receptor (CCR)6z immature dendritic cells (DCs). 2. Damaged
resident cell types produce inflammatory mediators (tumour necrosis factor (TNF)-a, heat shock protein-60 (HSP60)) and growth factors
that attract and activate the DC. 3. During viral infections, DCs phagocytose apoptotic virus-infected cells or are direct targets for viral
invasion. The local release of interferon (IFN)-c or virus-derived motifs (double-stranded ribonucleic acid (dsRNA)) further activates
the DC. 4. Alternatively, DCs can phagocytose bacteria. Certain bacterial patterns (lipopolysaccharide (LPS), Cytosine-p-Guanine
deoxyribonucleic acid (CpG DNA)) further activate the DCs. 5. The recognition of infection and tissue damage by DCs upregulates the
CCR7; DCs migrate to the T-cell area of draining lymph nodes where the ligand MIP3b is constitutively expressed. 6. In the T-cell area,
DCs produce chemokines to attract naive T-cells that continuously leave the bloodstream via the high endothelial venules (HEV). 7.
Naive T-cells are first arrested and then selected for specificity for microbial antigens. The latter event induces their activation. 8. The
activation of T-cells leads to autocrine production of interleukin (IL)-2 and to clonal expansion of antigen-specific CD4z and CD8z
T-cells. These cells differentiate into effector cells that leave the lymph node via the efferent lymphatic. Effector cells have the capacity to
kill infected cells or to activate macrophages. 9. Upon contact with DCs, some antigen-specific CD4zT-cells upregulate CXCR5 receptor
and migrate to the B-cell follicles of the draining lymph node. Here, they further interact with germinal centre DCs to induce CD40L-
dependent B-cell immunoglobulin (Ig) switching and affinity maturation (germinal centre reaction). Most high-affinity B-cells go to the
bone marrow to become long-lived Ig-producing plasma cells. Th: T-helper; CTL: cytotoxic lymphocyte; GM-CSF: granulocyte
macrophage colony stimulating factor.
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lymph nodes. This process is exceptional in that
maturing DCs have to migrate against chemotactic
gradients that attract immature DCs into the inflam-
matory site. To achieve this, maturing DCs produce
inflammatory chemokines leading to ligand-induced
downregulation of CCR1, 5 and 6 receptors. How-
ever, the expression of CCR7 is increased [51, 58].
A ligand for CCR7 is secondary lymphoid tissue
chemokine (SLC; 6Ckine), which is expressed at
afferent lymphatic endothelium, efficiently guiding
DCs into the afferent lymphatics. Another ligand for
CCR7 is MIP-3b (Epstein-Barr virus-induced mole-
cule 1 ligand chemokine), which is constitutively
expressed in T-cell zones of lymph nodes, possibly
attracting maturing DCs and naive T-cells into these
areas [59]. The importance of directed migration of
DCs into the lymph nodes is underscored in CCR7
knock-out mice or SLC mutant mice who fail to
mount a primary immune response [59].
The migration of airway DCs in response to an
immunogenic stimulus is rapid; within 12 h, lung-
derived DCs can be traced in the T-cell area of
draining mediastinal lymph nodes of the lung [5, 6,
19, 60]. DCs reaching the draining lymph nodes are
fully mature and specialized to stimulate naive T-cells.
Moreover, they produce high levels of constitutive
chemokines, such as DC chemokine and MIP-3b,
which attract naive T-cells [3, 59]. Not surprisingly,
when antigen is delivered by DCs in the airways, the
initial activation and first cycle of division in naive
T-cells occur in the draining mediastinal lymph nodes
[6]. When a new protein antigen is presented by DCs
in the airways, activation followed by proliferation
occurs almost exclusively in antigen-specific T-cells.
Under these conditions, there is minimal induction of
bystander activation in nonantigen specific cells [6].
This process is very rapid as some antigen-specific
T-cells have already undergone two cell divisions
48 h after introducing antigen into the lung. After
3–4 days, effector CD4z and CD8z lymphocytes are
generated in the draining lymph nodes, which then
leave the lymph node via the efferent lymphatics and
recirculate throughout the body [6, 47]. In contrast to
most naive L-selectinzT-cells, these activated effector
cells are predisposed to migrate to inflammatory
tissues by their strong expression of inflammatory
chemokine receptors (CCR1, CCR2, CCR5, CXC1),
integrins, CD44 hyaluronate receptor, and by down-
regulation of L-selectin [61]. Other effector CD4z
T-cells are stimulated by OX40L on DCs to upregu-
late the CXCR5 and to migrate into lymph node
germinal centres where the ligand B-cell attracting
chemokine is expressed [59]. These CD4 effectors
produce IL-4, stimulate B cell Ig production, and
induce the germinal centre reaction, critical for the
generation of high-affinity antibodies [62].
Effector and memory CD4z and CD8z lympho-
cytes are poised to migrate to sites of inflammation or
virus replication within the lung, and, upon recogni-
tion of their cognate ligand, will regulate the lung
defence mechanisms to clear the pathogen (see later).
There is now further evidence that the lung DC is the
most important APC in stimulating effector CD4z
cells, as was recently shown for the response to
inhaled soluble antigen in rodents [32, 37]. This
interaction is likely to occur within the inflamed
airways and lung parenchyma and does not require a
migratory DC. The nonmigratory DCs situated
around lung venules and within the alveolar wall,
are, therefore, ideal candidates for presentation and
amplification of effector T-cell reactions during the
effector and/or memory response, especially when
resident AMs have become immunostimulatory, e.g.
under the influence of locally released GM-CSF and
TNF-a [37, 39].
Dendritic cells and immunity to viruses
Innate immunity against viral infections depends
upon type I IFNs (IFN-a/b), which interfere with viral
replication (hence their name) by induction of
a number of IFN-stimulated genes. Additionally,
IFN-a/b increases MHC class I expression on virus-
infected cells and activates NK cells. Although type I
IFNs are produced by virus-infected epithelial cells
and fibroblasts, another important early source of
large amounts of IFN-a/b is the circulating pool of
enigmatic natural IFN-producing cells (IPC), which
are rapidly attracted to sites of viral replication and
inflammatory lymph nodes [63]. There is now consi-
derable evidence that these IPCs are identical to the
plasmacytoid monocytes or CD4zCD11c- blood pre-
cursors of type 2 lymphoid DCs (pre-DC2) [24, 64].
Interestingly, viral infection of IPCs in the absence of
exogenous cytokines induces their differentiation into
lymphoid DC2s that produce extremely high levels of
antiviral IFN-a/b [63]. Moreover, virus-infected DC2
cells have the capacity to stimulate naive T-cells to
become IFN-c and IL-10 producing effectors. The
release of IFN-a by IPCs and virus-infected cells will
further promote the maturation and migration of
tissue-resident myeloid DCs, also contributing to the
generation of antiviral effector T-cells. Therefore,
pre-DC2s/IPCs that are attracted into sites of viral
infection perform the two master functions of the
innate immune system: 1) they kill viruses; and 2) they
initiate and dictate adaptive immune responses [1].
The involvement of these cells in viral lung infections
has not been studied but clearly deserves much
attention.
NK cells are another important aspect of innate
immunity to viruses, not least by their capacity
to perform antibody-dependent cellular cytotoxicity,
their potential to induce apoptosis in target cells and
their secretion of IFN-c. Murine studies have shown
that DCs can directly activate the cytotoxic activity
of NK cells through membrane interactions (CD80,
CD40L) and by production of IFN-a, IL-12, IL-15
and IL-18 [65]. A population of oligoclonal T-cells,
called NKT-cells, respond to their natural microbial
ligand a-galactosyloceramide, presented on the non-
classical MHC class I molecule CD1d and expressed
on DCs [3]. Although the latter event strongly induces
IFN-c production in responding NKT-cells, it is
also possible that IL-4 is produced under certain
conditions (e.g. presentation by DC2) [3].
The adaptive immune response to viral infection
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involves a population of CD8zcytotoxic lymphocytes
(CTLs), which have the capacity to kill virus-infected
cells and which constitute immunological memory
to infection. The TCR on CD8z CTLs recognizes
cytosol-derived viral peptides presented on MHC class
I molecules. All of the body9s cells express MHC
class I, but only professional APCs have the necessary
costimulatory molecules to stimulate naive CD8z
CTL cells. Therefore, induction of immunity in the
CD8z pool requires that: 1) DCs are infected with
virus (endogenous pathway of MHC class I loading);
or 2) that they acquire exogenous viral antigen from
other infected cells (exogenous pathway of MHC class
I loading). A number of viruses (influenza virus,
respiratory syncytial virus, measles virus (MV), herpes
virus, cytomegalovirus, and dengue virus) can directly
infect myeloid and lymphoid DCs in vitro [63, 66].
For example, infection with influenza virus occurs in
almost all DCs exposed to the virus, as seen in their
expression of haemagglutinin and nonstructural pro-
tein 1 [67]. The infection must not, however, lead to
rapid cell death, as this would eliminate induction of
immunity. To avoid destruction, DCs produce IFN-a,
which induces the MxA gene to protect the cell from
the cytopathic effects of viral infection [56]. Active
viral replication is not a requirement, as inactivated
influenza virus presented by DCs induces strong
CTL activity in vitro [67]. When infection or active
replication do not occur within DCs, an efficient,
alternative pathway to generate MHC class I viral
peptides is the phagocytosis of virus particles or virus-
infected epithelial cells that have become apoptotic, a
process called cross-presentation [68].
As the respiratory tract is often the site of primary
viral replication of many of the previously mentioned
viruses, it is evident that the airway DC is the most
relevant APC for viral infections in vivo, as suggested
in a number of viral models of influenza and Sendai
virus [46, 47]. Airway DCs express: 1) specific recep-
tors that are used by viruses to enter the cell, e.g. the
ICAM-1 receptor for rhinovirus, and the CD46
receptor for measles virus; but also 2) the mannose
receptor that is used to recognize sugar moieties on
the capsular and envelope glycoproteins on a variety
of viruses [35, 69]. The cross-presentation pathway is
also particularly relevant for loading lung DCs with
exogenous virus antigen, as apoptosis is the dominant
mechanism by which many respiratory viruses induce
damage to bronchial and alveolar epithelial cells.
It is controversial whether the induction of full
cytotoxic activity in CD8z cells by DCs requires
CD4z Th1 cell help. Like T-cell-dependent antibody
production by B-cells, many CD8z cytotoxic cell
responses are dependent on CD4zTh1 cells, provid-
ing IL-2 for proliferation and IFN-c for activation
(fig. 4). In the "licence to kill" theory, originally
proposed by LANZAVECCHIA [70], it is thought that
CD40L expressed on virus-specific CD4z T-cells
activates the DC to prime CD8z CTL activity. The
interaction between CD4zTh1 cells and CD8zCTLs
is therefore indirect and does not occur simulta-
neously, with the DC acting as a temporal bridge. It is,
however, possible that direct viral infection of DCs as
well as microbial stimuli (LPS, microbial DNA) can
bypass the need for CD4zTh1 help [71].
One final aspect of long-lived adaptive immunity to
infections within the respiratory tract is the presence
of secretory IgA in epithelial lining fluid, inhibiting
viral (and bacterial) adherence. The production of
IgA antibodies is T-cell-independent, but requires
cytokines from nonB-cells. Dendritic cells: 1) induce
surface IgA expression on CD40-activated naive
B-cells; and 2) through their release of IL-10, TGF-b
and an unknown factor induce secretion of both IgA1
and IgA2 subclasses by plasma cells [72]. It has been
suggested that direct interactions between B-cells,
DCs and epithelial cells (providing IL-5) occur locally
in the airway epithelium, leading to the extralymphoid
production of IgA [54].
Dendritic cells and immunity to bacteria, fungi and
parasites
Innate immunity to bacterial and fungal pathogens
consists mainly of b-defensins, bacteriostatic enzymes,
alternative activation of complement, production of
C-reactive protein and most importantly, uptake
followed by phagocytic cell killing (respiratory
burst). Phagocytic neutrophils and monocytes pre-
dominate in acute pyogenic infections, whereas
macrophages are more prevalent in chronic or
granulomatous infections. Another important func-
tion attributed to NK cells is recognizing conserved
bacterial structures and effectively killing cells infected
with intracellular bacteria (e.g. L. monocytogenes).
In contrast to most T-lymphocytes that express a
unique ab TCR, a subclass of intraepithelial CD4-
CD8- T-cells express a common cd TCR. This TCR
reacts with glycolipid antigens in a CD1-restricted
manner and could be important for recognizing
conserved motifs of intracellular bacteria.
Adaptive immunity to bacteria is both humoral and
cellular. Neutralizing immunoglobulins and epithelial
IgA protect against extracellular organisms through a
variety of mechanisms: neutralization of toxins, com-
plement lysis, and interference with adherence to cell
surfaces [17]. Opsonizing antibodies are important for
complement fixation and for enhancing the efficiency
of macrophage killing. T-lymphocytes mediate a
variety of reactions, including recruitment and activa-
tion of macrophages, induction of delayed hyper-
sensitivity (granuloma formation) and the provision
of help for Ig production by B-cells. The central role
of lymphocytes in protecting against infection is
illustrated in acquired immune deficiency syndrome
(AIDS), where a progressive loss of CD4z cells leads
to a dramatic susceptibility to bacterial, fungal and
viral pathogens. Over the last 15 yrs, it has become
clear that it is not the induction of an immune
response per se that determines the outcome of a
pulmonary bacterial infection, but rather the develop-
ment of a response that is optimally tuned to clear the
pathogen. Inappropriate responses to infection can
cause severe pathology. Central to the understanding
of adaptive immunity to bacterial infections was the
discovery of the Th1/Th2 concept by MOSSMANN et al.
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[16]. By the nature of their antagonistic effects on the
opposite subset (e.g. IL-4 suppressing IFN-c in Th1
cells), the relative frequencies of the two Th subsets
can determine whether a given immune response is
protective or pathological [17]. In the murine model of
Leismania major infection, Th1 cells are associated
with protection, whereas Th2 cells are clearly asso-
ciated with susceptibility, leading to a fatal disease
[17]. For bacteria, the adaptive immune response has
evolved to induce a strongly polarized Th1 response
to clear the infection. This is especially critical for
intracellular bacteria that depend on IFN-c: 1) to
activate macrophages to either contain (e.g. in the case
of tuberculosis) or eradicate the infection; and 2) to
switch Ig production towards opsonizing IgG2a. Th2
cells are inadequate in both respects.
In the absence of bacterial stimuli, resting lung
myeloid DCs induce weak Th2 responses to inhaled
harmless antigens [19, 26]. This may be due to the
pulmonary environment, which is rich in IL-10 or
PGE2, mediators known to downregulate IL-12 pro-
duction in DCs [22, 36]. This response can be
dramatically changed during bacterial infection.
According to KALINSKI et al. [22], the characteristics
of the pathogen and the microenvironmental tissue
damage that it induces are instrumental in directing
the type of Th response that will ensue, to ensure
an optimal immune response. Several pathogen-
associated molecules (LPS, lipoteichoic acid, peptido-
glycan, bacterial DNA) have been shown to induce
IL-12 and/or IL-18 production from DCs, and to
induce their migration into T-cell areas, effectively
inducing IFN-c-producing Th1 cells [20, 26, 57].
While it is clear that the majority of "danger" signals,
such as LPS, activate DCs to promote a Th1 response,
the nature of the pathogen-associated molecules
involved in initiating a Th2 response are poorly
understood. These molecules could be used by the
pathogen to subvert the cellular immune response. As
an example, a filarial nematode-secreted glycoprotein
called ES-62 was shown to influence Th2 development
by DCs even in the presence of IL-12 [25]. For this
parasite, Th2 responses are associated with decreased
clearance from the tissues.
Mycobacterial infection deserves separate attention.
Immunity to mycobacteria is mediated via macro-
phages, whose activation depends upon IFN-c-
producing CD4zTh1 cells, and by CD8zCTLs that
lyse infected macrophages harbouring cytoplasmic
mycobacteria. Recently, it was shown that cd T-cells
and CD8z T-cells reacting to mycobacterial glyco-
lipids on CD1 molecules are also important in
mediating control of the disease [73]. Although
macrophages have been shown to be potent inducers
of effector T-cells in vitro, studies in mice have shown
that DCs can also efficiently phagocytose the atten-
uated BCG strain and migrate to the draining lymph
nodes of the lung to induce protective immunity
against Mycobacterium tuberculosis challenge in vivo
[18]. In humans, the presence of the primary Ghon
complex is a clear illustration of the movement of
mycobacteria from the site of inoculation to the
draining lymph nodes. It is likely that DCs are the
vehicles of this transport. Moreover, it has been
shown that human DCs phagocytose M. tuberculosis
and efficiently prime mycobacterium-specific CD4z
and CD8z T-cells in vitro, with at least some
mycobacterial antigens being presented on CD1 [74].
Granuloma formation is a consistent finding in
infections caused by mycobacteria, reflecting the need
to contain the organism when it is not efficiently
cleared by macrophages. It was recently shown that
early granulomata induced by BCG in rats are
characterized by large numbers of DCs expressing
the rat marker OX62 [75]. These DCs were seen to
interact with T-cells in the lymphoid collar surround-
ing the area of epithelioid cells and Langhans9 giant
cells. As the granulomata matured, increasing num-
bers of DCs were seen to surround the lesion.
Similarly, patients with the less aggressive tuberculoid
leprosy (M. leprae) have multiple CD1z DCs sur-
rounding the granulomata, whereas those with pro-
gressive lepromatous lepra lack infiltrating DCs [76].
The latter findings suggest that DC infiltration into
the granuloma is critical in containing infection. Thus,
as DCs have the capacity to activate effector T-cells,
it is unclear why these granulomata do not resolve.
One possible explanation could be the production
of large amounts of the Th2 cytokine IL-10 within
granulomata, known to reduce costimulatory acti-
vity and IL-12 production in DCs and to convert
the phenotype of mycobacterium-infected DCs into
bactericidal macrophage-like cells [3, 36].
Dendritic cells and immunodeficiency
As DCs are central to the integration of innate and
adaptive immunity, it is highly likely that disruption
of DC function leads to increased susceptibility to
infection. Indeed, DCs have been implicated in the
pathogenesis of a variety of acquired immuno-
deficiency states. Measles infection causes a profound
immune suppression, which leads to an increased
susceptibility to secondary infections, a major cause of
childhood mortality in developing countries. Respira-
tory tract DCs are a primary target for MV infection
and dissemination to lymph nodes. Infection of DCs
with MV leads to the formation of giant multi-
nucleated reticuloendothelial cells (Whartin-Finkeldey
cells) that are thought to represent syncytia of DCs
and activated T-cells, and are sites of vigorous viral
replication [77]. Infected DCs actively suppress
"bystander" T-cell proliferation, and when they
interact with activated T-cells, both cell types are
eliminated by apoptosis [77, 78]. Moreover, MV infec-
tion also causes defective activation and suppression
of IL-12 production by DCs. Not surprisingly, inter-
action of MV with DCs leads to a profound defect
in cell-mediated immunity, as exemplified by the loss
of the delayed type hypersensitivity reaction to recall
antigens [66]. Similarly, the interaction of mucosal
DCs and human immunodeficiency virus (HIV) leads
to transmission of the virus to the lymph nodes [79].
Surface receptors, such as CD4, the costimulatory
molecule DC-SIGN and the chemokine receptor
CCR5, are used by the virus to attach to the DC
surface, or to enter the cell [11]. Upon interaction
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with virus-carrying DCs, naive CD4zT-cells become
infected with the virus, ultimately causing their
destruction [80]. Aside from their role in dissemina-
tion of HIV, it is thought that DCs can function as an
important reservoir of HIV during the latent phase of
the disease. When patients with HIV infection reach
the AIDS stage, there is a striking reduction in the
natural IFN-producing cells, recently identified as
pre-DC2s (see earlier), although its implication in the
progression of immunodeficiency is not established
[64].
The use of systemic corticosteroids is associated
with a reduction in cell-mediated immunity, leading to
enhanced susceptibility to a number of pathogens.
Corticosteroids reduce the antigen-uptaking capacity
of DCs and influence the expression of costimulatory
molecules and the level IL-12 production [81, 82].
Moreover, inhaled steroids have been shown to reduce
the numbers of airway DCs by inducing apoptosis,
although it is unclear whether this alone can lead to
immunosuppression [83].
Dendritic cells as cellular vaccines for infectious
diseases?
The fact that DCs are crucial inducers of adaptive
immunity has led to their exploitation as potential
cellular vaccines, inducing long-lasting immunity that
may mimic that of natural infection. During the last
2 yrs, numerous clinical trials using DCs to induce
strong CTL activity against tumours have been
initiated, highlighting the feasibility of such an
approach [3]. Similarly, the possible use of DCs to
protect against viral or bacterial infection is actively
investigated in a number of laboratories. Dendritic
cells pulsed with a lymphocytic choriomeningitis virus
peptide were able to induce strong CTL activity and
protect against subsequent live virus infection in mice
[84]. Similarly, human DCs pulsed with influenza
peptide were able to elicit long-lasting CTL activity
in vivo, although protection against subsequent infec-
tion was not tested [85]. In mouse studies, it was
also recently shown that pulsing DCs in vitro
with Chlamydia trachomatis antigen, Pseudomonas
aeruginosa antigen and attenuated Mycobacterium
spp. was sufficient to protect against subsequent
challenge of the lungs with live organisms [18, 86,
87]. Although it is not feasible to vaccinate large
numbers of patients with (autologous) DCs in the
prevention of infections, alternative strategies could
be aimed at targeting a vaccine to the resident DCs
of the body. In this context, it is clear that the anti-
gens encoded by DNA vaccines are expressed and
presented predominantly by DCs in the lymph
nodes draining the site of injection [88]. Alternatively,
the administration of attenuated bacteria (e.g.
apathogenic Salmonella typhimurium subspecies) that
are genetically modified to express novel antigens,
might be a future strategy for loading DCs in situ, as
these strains are actively phagocytosed by immature
DCs [89].
Concluding remarks
The defence system of the host lung against micro-
bes relies on the communication between cells of the
innate and adaptive immune system. Dendritic cells
use the receptors of the innate immune system to
recognize and internalize pathogens, and carry these
antigens to the draining lymph nodes. Over the past
few years, it has become clear that these cells perform
essential and pivotal functions in the induction and
regulation of adaptive cellular and humoral immunity.
The knowledge of dendritic cell biology is rapidly
expanding; in the future, it will undoubtedly be
possible to see strategies that will utilize the unique
properties of these cells for the prevention and therapy
of infectious diseases.
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